Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV000001290 | SCV000474016 | pathogenic | Mucopolysaccharidosis, MPS-III-C | 2024-07-22 | criteria provided, single submitter | clinical testing | |
Genomic Research Center, |
RCV000001290 | SCV000784408 | pathogenic | Mucopolysaccharidosis, MPS-III-C | 2018-03-05 | criteria provided, single submitter | clinical testing | |
Genomic Research Center, |
RCV000662072 | SCV000784409 | pathogenic | Retinitis pigmentosa 73 | 2018-03-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001390806 | SCV001592654 | pathogenic | Mucopolysaccharidosis, MPS-III-C; Retinitis pigmentosa 73 | 2023-12-20 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Asp449Glyfs*21) in the HGSNAT gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in HGSNAT are known to be pathogenic (PMID: 17033958, 19479962). This variant is present in population databases (rs483352894, gnomAD 0.0009%). This premature translational stop signal has been observed in individual(s) with mucopolysaccharidosis type IIIC (PMID: 16960811, 19479962, 31228227). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 1231). For these reasons, this variant has been classified as Pathogenic. |
OMIM | RCV000001290 | SCV000021440 | pathogenic | Mucopolysaccharidosis, MPS-III-C | 2006-10-01 | no assertion criteria provided | literature only |